Overview

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

Status:
Active, not recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

This study will assess the effect of a Proton Pump Inhibitor (PPI) (rabeprazole) on the pharmacokinetics (PK) of PC14586 and the effect of an H2-receptor antagonist (famotidine) on the PK of PC14586

Phase:

Phase 1

Details

Lead Sponsor:

PMV Pharmaceuticals, Inc

Treatments:

Famotidine
Rabeprazole